T. Rowe Price Investment Management’s Rapport Therapeutics RAPP Stock Holding History

T. Rowe Price Investment Management’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.4M	Buy	620,600 +1,571	+0.3%	+$44.2K	0.01%	469
2025 Q4	$18.8M	Sell	619,029 -88,479	-13%	-$2.45M	0.01%	508
2025 Q3	$21M	Buy	707,508 +93,689	+15%	+$1.67M	0.01%	494
2025 Q2	$6.98M	Sell	613,819 -938,106	-60%	-$9.95M	﹤0.01%	571
2025 Q1	$15.6M	Sell	1,551,925 -85,006	-5%	-$1.1M	0.01%	538
2024 Q4	$29M	Sell	1,636,931 -90,180	-5%	-$2M	0.02%	479
2024 Q3	$35.4M	Buy	1,727,111 +191,960	+13%	+$4.13M	0.02%	457
2024 Q2	$35.7M	Buy	+1,535,151	New	+$35.5M	0.02%	442

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

T. Rowe Price Investment Management's RAPP Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Rapport Therapeutics (RAPP) stake by 0.25% in Q1 2026, buying an estimated $44.2K and bringing the position to 620,600 shares worth $19.4M. The position accounts for 0.01% of the portfolio, ranked #469.

T. Rowe Price Investment Management first reported a position in RAPP in Q2 2024 and has held it in 8 quarters since. The position peaked at $35.7M in Q2 2024. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

T. Rowe Price Investment Management held 620,600 shares of Rapport Therapeutics worth $19.4M as of Q1 2026.
T. Rowe Price Investment Management bought 1,571 Rapport Therapeutics shares in Q1 2026, an estimated $44.2K.
Rapport Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #469 holding.
T. Rowe Price Investment Management first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 8 quarters since.
T. Rowe Price Investment Management's Rapport Therapeutics position peaked at $35.7M in Q2 2024.
147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.